Friday, 6 November 2026
M
Meridian Globe
Live briefing
Toyota to bring Celica back to premier rally racing after 32-year break— 日经 Nikkei AsiaU.S. Steel grows to 40% of Nippon Steel profit as prices surge— 日经 Nikkei AsiaThe price of building Japanese stealth frigates in Australia— 日经 Nikkei AsiaMcDonald's wages war on KFC in Japan as consumers crave chicken— 日经 Nikkei AsiaJapan's Koito looks to keep lighting way with smart automotive lamps— 日经 Nikkei AsiaAnalysis: How a secret feud ignited Xi Jinping's governance drive— 日经 Nikkei AsiaJapan lender leads $600m credit line to help Malaysia's Petronas cut CO2— 日经 Nikkei AsiaToyota supplier buys Nissan-linked peer amid China competition— 日经 Nikkei AsiaToyota to bring Celica back to premier rally racing after 32-year break— 日经 Nikkei AsiaU.S. Steel grows to 40% of Nippon Steel profit as prices surge— 日经 Nikkei AsiaThe price of building Japanese stealth frigates in Australia— 日经 Nikkei AsiaMcDonald's wages war on KFC in Japan as consumers crave chicken— 日经 Nikkei AsiaJapan's Koito looks to keep lighting way with smart automotive lamps— 日经 Nikkei AsiaAnalysis: How a secret feud ignited Xi Jinping's governance drive— 日经 Nikkei AsiaJapan lender leads $600m credit line to help Malaysia's Petronas cut CO2— 日经 Nikkei AsiaToyota supplier buys Nissan-linked peer amid China competition— 日经 Nikkei Asia

Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Source Nature 医学研究9d ago
Summary

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
Health
Region
Global
Language
English
Item ID
health-a90987bb

Comments 0 comments

No comments yet. Be the first.

Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial · Meridian Globe